ProMIS Neurosciences, Inc. (PMN)
NASDAQ: PMN · Real-Time Price · USD
7.91
+0.28 (3.60%)
At close: Dec 5, 2025, 4:00 PM EST
7.90
0.00 (-0.06%)
After-hours: Dec 5, 2025, 6:47 PM EST
ProMIS Neurosciences Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
8
Market Cap
17.02M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
PMN News
- 5 days ago - ProMIS Neurosciences Announces New Peer-Reviewed Publication Showing Plasma pTau as a Predictive Early Endpoint in Alzheimer's trials, Supporting its Ongoing Phase 1b PRECISE-AD trial with PMN310 - GlobeNewsWire
- 5 days ago - ProMIS Neurosciences to Participate in the 8th Annual Evercore Healthcare Conference - GlobeNewsWire
- 12 days ago - ProMIS Neurosciences Announces Reverse Stock Split - GlobeNewsWire
- 24 days ago - ProMIS Neurosciences Announces Third Quarter 2025 Financial Results & Corporate Highlights - GlobeNewsWire
- 4 weeks ago - ProMIS Neurosciences to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference - GlobeNewsWire
- 6 weeks ago - ProMIS Neurosciences Strengthens Board with Appointment of Slanix Paul Alex, Pharm.D., President and Portfolio Manager, Public Equity of Ally Bridge Group - GlobeNewsWire
- 3 months ago - ProMIS Neurosciences Receives DSMB Approval to Advance to Final Dose Escalation Cohort in Phase 1b Alzheimer's Trial of PMN310 - GlobeNewsWire
- 4 months ago - ProMIS Neurosciences Announces Second Quarter 2025 Financial Results & Corporate Highlights - GlobeNewsWire